VIVEK SUBBIAH to Immunohistochemistry
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Immunohistochemistry.
Connection Strength
0.246
-
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J Hematol Oncol. 2014 Jan 14; 7:8.
Score: 0.054
-
Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1). PLoS One. 2013; 8(7):e68985.
Score: 0.053
-
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol Cancer Ther. 2012 Nov; 11(11):2541-6.
Score: 0.049
-
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One. 2011 Apr 06; 6(4):e18424.
Score: 0.045
-
Gastric adenocarcinoma in children and adolescents. Pediatr Blood Cancer. 2011 Sep; 57(3):524-7.
Score: 0.044